Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 42 |
| Active Pipeline (Recruiting Now) | 14 (7) |
| Completed vs Stopped Early | 6 / 7 (16.7%) |
| Median Closed Actual Enrollment | 52 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Vancouver General Hospital | Vancouver, British Columbia | 7 |
| Sunnybrook Health Sciences Centre | Toronto, Ontario | 3 |
| UC Davis Comprehensive Cancer Center | Sacramento, CA | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04812366 | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University of British Columbia Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.